Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 01, 2024

Efficacy of Ocrelizumab vs Interferon/Glatiramer Acetate in People With MS Older Than 60 Years

Journal of Neurology, Neurosurgery, and Psychiatry


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Neurology, Neurosurgery, and Psychiatry
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60
J. Neurol. Neurosurg. Psychiatr. 2024 Mar 07;[EPub Ahead of Print], YC Foong, D Merlo, M Gresle, K Buzzard, M Zhong, WZ Yeh, V Jokubaitis, M Monif, O Skibina, S Ozakbas, F Patti, P Grammond, MP Amato, T Kalincik, D Horakova, E Kubala Havrdova, B Weinstock-Guttman, J Lechner Scott, C Boz, MJ Sa, H Butzkueven, A van der Walt, C Zhu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading